证券代码：301363 证券简称：美好医疗 公告编号：2025-067 深圳市美好创亿医疗科技股份有限公司 关于首次公开发行前已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为深圳市美好创亿医疗科技股份有限公司（以下简 称"公司"、"发行人"）首次公开发行前已发行的股份。本次解除限售股东户数 共计5户，解除限售股份数量为412,300,000股，占公司总股本的72.4769%，限售 期为自公司首次公开发行股票并上市之日起36个月。 2、本次解除限售股份的上市流通日期为2025年10月16日（星期四）。 一、公司首次公开发行和股本变动情况 根据中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2022〕1441号）和深圳证券交 易所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上 市的通知》（深证上〔2022〕986号），公司首次向社会公众公开发行人民币普 通股（A股）4,427万股，并于2022年10月12日在深圳证券交 ...

关于深圳市美好创亿医疗科技股份有限公司 首次公开发行前已发行股份解除限售并上市流通 的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为深圳 市美好创亿医疗科技股份有限公司（以下简称"美好医疗"、"上市公司"或"公 司"）首次公开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐 业务管理办法（2025 年修订）》《深圳证券交易所创业板股票上市规则（2025 年 修订）》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作（2025 修订）》等相关法律、法规和规范性文件的规定，对美好医疗首次公 开发行前已发行股份解除限售并上市流通事项进行了核查，具体情况如下： 一、公司首次公开发行和股本变动情况 根据中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号）和深圳证券交 易所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上 市的通知》（深证上〔2022〕986 号），公司首次向社会公众公开发行人民币普通 股（A 股）4,427 万股，并于 2022 年 10 月 12 ...

Core Viewpoint - On October 10, Meihao Medical experienced a decline of 1.82% with a transaction volume of 111 million yuan, indicating a high level of trading activity and investor interest in the stock [1] Financing Summary - On October 10, Meihao Medical had a financing buy-in amount of 15.31 million yuan and a financing repayment of 11.07 million yuan, resulting in a net financing buy-in of 4.24 million yuan [1] - As of October 10, the total financing and securities lending balance for Meihao Medical was 194 million yuan, with the financing balance accounting for 5.20% of the circulating market value, which is above the 90th percentile level over the past year [1] - The company had no shares repaid in securities lending on October 10, with 1,300 shares sold short, amounting to 30,900 yuan at the closing price [1] - The securities lending balance was 986,400 yuan, also exceeding the 90th percentile level over the past year [1] Company Overview - Meihao Medical, established on July 15, 2010, and listed on October 12, 2022, is located in Longgang District, Shenzhen, Guangdong Province, specializing in the design, development, manufacturing, and sales of medical device components [2] - The main revenue sources for Meihao Medical include home respiratory machine components (59.48%), home and consumer electronics components (14.61%), other medical product components (10.33%), cochlear implant components (8.16%), precision molds and automation equipment (5.63%), and other categories (1.09%) [2] - For the first half of 2025, Meihao Medical reported a revenue of 733 million yuan, a year-on-year increase of 3.73%, while the net profit attributable to the parent company was 114 million yuan, a year-on-year decrease of 32.44% [2] Dividend and Shareholder Information - Since its A-share listing, Meihao Medical has distributed a total of 248 million yuan in dividends [3] - As of June 30, 2025, the top ten circulating shareholders included Huabao Zhongzheng Medical ETF (512170) as the second-largest shareholder with 5.694 million shares, an increase of 1.6179 million shares from the previous period [3] - New shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B (000727) with 5 million shares, and several other funds have increased their holdings, while some have exited the top ten list [3]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The trend of Chinese innovative drugs going overseas is a long-term phenomenon, with external environmental changes having limited impact. In the first half of 2025, there were 72 License-out transactions, exceeding half of the total for 2024, with a total transaction amount 16% higher than in 2024. Notably, there were 16 transactions exceeding $1 billion each [2] - The small nucleic acid drug sector has seen significant breakthroughs, particularly in the treatment of chronic diseases such as hypertension and hyperlipidemia, with major collaborations and potential milestone payments indicating a robust commercial outlook [3] - The trend towards oral autoimmune drugs is gaining attention, with significant partnerships and clinical advancements in this area, highlighting the importance of oral formulations in autoimmune therapies [4] - Recent clinical data on long-acting insulin analogs shows promising weight loss results, with ongoing developments in combination therapies for metabolic diseases, indicating a growing market potential [5] - The CXO sector is gradually recovering, with an increase in License-out transactions serving as a vital funding source for biotech companies, leading to a resurgence in innovation and clinical development [6] - The 2025 national medical insurance negotiations and the commercial insurance innovative drug directory are crucial for companies involved, with a focus on orphan drugs and imported PD-1/L-1 products [7] Summary by Sections Industry Tracking - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a recent weekly decline of 1.20% and a monthly decline of 3.38%, ranking 25th among 31 industry indices [22][26] Industry Trends and Valuation - The pharmaceutical industry index currently has a PE ratio of 39.05, above the five-year historical average of 31.36, indicating a higher valuation compared to historical trends [48][50] Recent Research Achievements - The research team has published several in-depth reports on various pharmaceutical topics, including the growth of the blood products industry and the potential of GLP-1 drugs in chronic disease management [53] Important Policies and News - Recent regulations have been introduced to standardize clinical research and ensure drug traceability, which will impact the pharmaceutical landscape significantly [55][56]

Economic Indicators - The National Bureau of Statistics will release the CPI and PPI data for September on October 15, with expectations of a year-on-year CPI growth rate remaining flat and a month-on-month increase of 0.2% [1] - The PPI is anticipated to show a year-on-year decline of 2.4% and a month-on-month decrease of 0.3% [1] Financial Data - Additional financial data for September, including new loans, M2, and social financing, is expected to be released next week [2] Oil Price Adjustment - The next round of fuel price adjustments will occur on October 13 at 24:00, with a projected decrease of 20 yuan per ton for gasoline and diesel based on a reference crude oil price of $64.97 per barrel, reflecting a change rate of -0.34% [3] Trade Events - The 138th Canton Fair will be held from October 15 to November 4, featuring a record exhibition area of 1.55 million square meters and over 32,000 participating companies [4] - The 2025 Bay Area Semiconductor Industry Ecosystem Expo will take place from October 15 to 17 in Shenzhen, attracting over 600 leading companies and institutions from more than 20 countries [4] - The 2025 World Intelligent Connected Vehicles Conference will be held in Beijing from October 16 to 18, focusing on innovations in AI, communication, data utilization, and chip technology within the automotive industry [4] Stock Market Developments - A total of 41 stocks will face lock-up expiration next week, with significant unlocks including 577 million shares of China Merchants Port valued at 11.967 billion yuan and 412 million shares of Meihua Medical valued at 9.804 billion yuan [5][6] - Notable stocks with high unlock ratios include Meihua Medical, Andar Intelligent, and Kecuan Technology, all exceeding 50% [5] New Stock Opportunities - Five new stocks are set to be issued next week, including Marco Polo on October 13, He Yuan Bio on October 14, Chao Ying Electronics on October 15, Xi'an Yicai on October 16, and Bi Bei Te on October 17 [9][10]

Economic Data Release - The National Bureau of Statistics will release the CPI and PPI data for September on October 15, with expectations of a year-on-year CPI growth rate remaining flat and a month-on-month increase of 0.2% [1] - The PPI is anticipated to show a year-on-year decline of 2.4% and a month-on-month decrease of 0.3% [1] - Additional financial data such as new loans, M2, and social financing for September may also be released next week [2] Oil Price Adjustment - The next round of fuel price adjustments will occur on October 13 at 24:00, based on the "ten working days" principle [3] - As of October 10, the average price of reference crude oil was $64.97 per barrel, indicating a change rate of -0.34%, which suggests a potential decrease of 20 yuan per ton in domestic gasoline and diesel prices [3] Trade Fair and Conferences - The 138th Canton Fair will be held from October 15 to November 4 in Guangzhou, featuring a record exhibition area of 1.55 million square meters and over 32,000 participating companies [4] - The 2025 Bay Area Semiconductor Industry Ecosystem Expo will take place from October 15 to 17 in Shenzhen, attracting over 600 leading enterprises and institutions from more than 20 countries [4] - The 2025 World Intelligent Connected Vehicle Conference will be held in Beijing from October 16 to 18, focusing on innovations in AI, communication, data utilization, and chip technology within the automotive industry [4] Stock Unlocking Events - A total of 41 stocks will face unlocking next week, with significant unlocks including 577 million shares of China Merchants Port, valued at 11.967 billion yuan, and 412 million shares of Meihua Medical, valued at 9.804 billion yuan [5][6] - The unlocking ratios for several companies exceed 50%, including Meihua Medical, Andar Intelligent, and Kecuan Technology [5] New Stock Opportunities - Five new stocks are set to be issued next week, including Marco Polo on October 13, He Yuan Biological on October 14, Chaoying Electronics on October 15, Xi'an Yicai on October 16, and Bibet on October 17 [9][10]

Core Viewpoint - A total of 40 companies will have their restricted shares unlocked next week, amounting to 3.323 billion shares with a total market value of 79.774 billion yuan based on the closing price on October 10 [1] Group 1: Unlocking Schedule and Market Impact - The peak unlocking day is October 13, with 20 companies unlocking shares worth a total of 55.417 billion yuan, accounting for 69.46% of the total unlocking scale for the week [1] - The companies with the highest unlocking market value on October 10 are: China Merchants Port (11.967 billion yuan), Meihua Medical (9.804 billion yuan), and Weijie Chuangxin (8.207 billion yuan) [1] Group 2: Individual Company Unlocking Details - The companies with the largest number of unlocked shares are: China Merchants Port (577 million shares), Qingnong Commercial Bank (500 million shares), and Meihua Medical (412 million shares) [1] Group 3: Types of Restricted Shares - The types of unlocked shares include: 14 companies with original shareholders' restricted shares, 8 companies with restricted shares from directed placements, 6 companies with restricted shares from equity incentives, 5 companies with general equity incentive shares, 4 companies with original placement shares, 2 companies with original shareholders' strategic placement shares, and 1 company with strategic placement shares [1]

证券日报网讯 10月10日晚间，美好医疗发布公告称，经与会职工代表认真审议与民主选举，一致同意 选举周道福先生为公司第二届董事会职工代表董事。 （文章来源：证券日报） ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-066 深圳市美好创亿医疗科技股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事辞任情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）于近日收到公 司董事周道福先生的书面辞职报告。因工作安排原因，周道福先生申请辞去公司 非独立董事职务。周道福先生辞任后将继续担任公司副总经理职务，周道福先生 的辞任不会导致公司董事会人数低于法定最低人数，不存在应履行而未履行的公 开承诺，其书面辞职报告自送达公司董事会之日起生效。 二、选举职工代表董事情况 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《公司章程》等相关规定，公司于2025年10 月10日召开了职工代表大会。经与会职工代表认真审议与民主选举，一致同意选 举周道福先生（简历附后）为公司第二届董事会职工代表董事，任期至第二届董 事会届满之日止。 周道福先生原为公司第二届董事会非职工代表董事，变更为第二届董事会职 工代表董事后，公司第 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-065 深圳市美好创亿医疗科技股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现变更或否决议案的情形； 2、本次股东会不涉及变更前次股东会决议； 3、本次股东会采用现场表决与网络投票相结合的方式召开。 一、会议召开和出席情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）2025年第二次 临时股东会（以下简称"本次股东会"）于2025年10月9日（星期四）15:00召开， 公司已于2025年9月16日披露了《关于召开2025年第二次临时股东会的通知》（公 告编号：2025-064），具体内容详见公司在巨潮资讯网（www.cninfo.com.cn） 上披露的相关公告。本次股东会采用现场投票和网络投票相结合的方式召开，会 议有关事项具体如下： 1、现场会议召开时间：2025年10月9日（星期四）15:00 2、现场会议召开地点：广东省惠州市大亚湾西区龙山三路318号美好创亿产 业园A栋8楼801会议室 3、网络投 ...